"We recognise the need for increased but responsible transparency and welcome the recognition in the report of the steps being made by our industry. This has been at both European level with the launch of the EFPIA-PhRMA principles for responsible data sharing and at a UK level. At the ABPI we have continued to demonstrate our commitment to clinical trial transparency; through revisions to the ABPI Code of Practice, hosting multi-stakeholder technical workshops, a new clinical trial disclosure toolkit and a commitment to monitoring compliance. These are significant steps and demonstrate the ABPI’s leadership on the issue.
"However, research is a truly global activity and requires a consistent global approach. Any UK transparency requirements that sit on top of, and are separate from, European requirements will act as a disincentive for conducting clinical research in the UK.
"Today’s report is an important contribution to a complex debate that affects many people: patients, doctors, nurses, researchers, companies, government and regulators. The pharmaceutical industry is committed to working with all interested parties to discuss the recommendations in this report. As part of a global industry, we are actively engaging with our European and international counterparts, as well as many other stakeholders, to continue to work towards implementing and monitoring responsible clinical trial transparency at an international level."
Notes to editor
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. Our members supply 90 per cent of all medicines used by the NHS, and are researching and developing over two-thirds of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.
The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry, for statutory consultation requirements including the pricing scheme for medicines in the UK.